William H Polonsky

List of Publications by Year
in descending order

112 papers	10,532 citations	71102 41 h-index	33894 99 g-index
113 all docs	113 docs citations	113 times ranked	7115 citing authors

#	Article	IF	Citations
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
2	Impact of Real-Time CGM Data Sharing on Quality of Life in the Caregivers of Adults and Children With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2022, 16, 97-105.	2.2	13
3	Use of Connected Pen as a Diagnostic Tool to Evaluate Missed Bolus Dosing Behavior in People with Type 1 and Type 2 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 61-66.	4.4	4
4	A systematic review and meta-analysis to compare the prevalence of depression between people with and without Type 1 and Type 2 diabetes. Primary Care Diabetes, 2022, 16, 1-10.	1.8	56
5	Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review. Diabetes, Obesity and Metabolism, 2022, 24, 377-390.	4.4	23
6	Toward a more comprehensive understanding of the emotional side of type 2 diabetes: A re-envisioning of the assessment of diabetes distress. Journal of Diabetes and Its Complications, 2022, 36, 108103.	2.3	17
7	The Role of Retrospective Data Review in the Personal Use of Real-Time Continuous Glucose Monitoring: Perceived Impact on Quality of Life and Health Outcomes. Diabetes Technology and Therapeutics, 2022, 24, 492-501.	4.4	2
8	Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study). Diabetes Therapy, 2022, 13, 175-187.	2.5	19
9	The Influence of Real-Time Continuous Glucose Monitoring on Psychosocial Outcomes in Insulin-Using Type 2 Diabetes. Journal of Diabetes Science and Technology, 2022, , 193229682210948.	2.2	2
10	How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the OmnipodÂ® 5 System. Diabetes Research and Clinical Practice, 2022, 190, 109998.	2.8	15
11	Impact of Real-Time Continuous Glucose Monitoring Data Sharing on Quality of Life and Health Outcomes in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2021, 23, 195-202.	4.4	18
12	Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. Diabetes Care, 2021, 44, 141-149.	8.6	19
13	Tedious, Tiresome, and Dull: An Unrecognized Problem That We Can Solve. Diabetes Spectrum, 2021, 34, 85-89.	1.0	1
14	Exploring Why People With Type 2 Diabetes Do or Do Not Persist With Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Qualitative Study. Diabetes Spectrum, 2021, 34, 175-183.	1.0	2
15	Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey. Quality of Life Research, 2021, 30, 1629-1640.	3.1	1
16	Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study. Diabetes Technology and Therapeutics, 2021, 23, S-35-S-39.	4.4	34
17	Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin. JAMA - Journal of the American Medical Association, 2021, 325, 2262.	7.4	182
18	Overcoming psychological insulin resistance: A practical guide for healthcare professionals. Primary Care Diabetes, 2021, 15, 619-621.	1.8	0

#	Article	IF	Citations
19	â€œHyperglycemia aversivenessâ€• Investigating an overlooked problem among adults with type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107925.	2.3	11
20	Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts. Current Diabetes Reports, 2021, 21, 49.	4.2	13
21	Psychosocial aspects and contributions of behavioural science to medicationâ€taking for adults with type 2 diabetes. Diabetic Medicine, 2020, 37, 427-435.	2.3	6
22	Development of a Novel Tool to Support Engagement With Continuous Glucose Monitoring Systems and Optimize Outcomes. Journal of Diabetes Science and Technology, 2020, 14, 151-154.	2.2	3
23	Hypoglycemic Confidence in the Partners of Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 249-255.	4.4	6
24	Psychosocial Aspects of Diabetes Technology. Endocrinology and Metabolism Clinics of North America, 2020, 49, 143-155.	3.2	16
25	The influence of time in range on daily mood in adults with type 1 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107746.	2.3	10
26	Successful Health Care Provider Strategies to Overcome Psychological Insulin Resistance in United States and Canada. Journal of the American Board of Family Medicine, 2020, 33, 198-210.	1.5	3
27	Worries and concerns about hypoglycemia in adults with type 1 diabetes: An examination of the reliability and validity of the Hypoglycemic Attitudes and Behavior Scale (HABS). Journal of Diabetes and Its Complications, 2020, 34, 107606.	2.3	8
28	The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4). Diabetes Care, 2020, 43, 2017-2024.	8.6	34
29	When patient-reported experience does not match change in clinical outcomes: A perplexing view from the inside of a diabetes distress intervention. Journal of Diabetes and Its Complications, 2020, 34, 107533.	2.3	0
30	Impact of Participation in a Virtual Diabetes Clinic on Diabetes-Related Distress in Individuals With Type 2 Diabetes. Clinical Diabetes, 2020, 38, 357-362.	2.2	32
31	Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations. Journal of the Endocrine Society, 2019, 3, 1942-1957.	0.2	16
32	Economic costs of implementing group interventions to reduce diabetes distress in adults with type 1 diabetes mellitus in the T1-REDEEM trial. Journal of Diabetes and Its Complications, 2019, 33, 107416.	2.3	3
33	Identifying solutions to psychological insulin resistance: An international study. Journal of Diabetes and Its Complications, 2019, 33, 307-314.	2.3	23
34	Physicianâ€“patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes â€“ New findings from the global IntroDiaÂ® study. Diabetes Research and Clinical Practice, 2019, 149, 89-97.	2.8	10
35	Addressing diabetes distress in clinical care: a practical guide. Diabetic Medicine, 2019, 36, 803-812.	2.3	124
36	Toward effective interventions to reduce diabetes distress among adults with type 1 diabetes: Enhancingâ€‰Emotion regulation and cognitive skills. Patient Education and Counseling, 2019, 102, 1499-1505.	2.2	10

#	Article	IF	Citations
37	Diabetes and depression were not associated in Venezuelan adults: The EVESCAM study, a national cross-sectional sample. Primary Care Diabetes, 2019, 13, 441-445.	1.8	3
38	Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis. BMJ Open Diabetes Research and Care, 2019, 7, e000723.	2.8	12
39	Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDiaÂ® study. Diabetes Research and Clinical Practice, 2019, 148, 179-188.	2.8	2
40	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technology and Therapeutics, 2018, 20, 274-284.	4.4	88
41	The impact of non-severe hypoglycemia on quality of life in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 373-378.	2.3	24
42	Response to Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425â€“1432. Diabetes Care, 2018, 41, e18-e18.	8.6	0
43	Motivation and attitudes toward changing health (MATCH): A new patient-reported measure to inform clinical conversations. Journal of Diabetes and Its Complications, 2018, 32, 665-669.	2.3	19
44	Emotion regulation contributes to the development of diabetes distress among adults with type 1 diabetes. Patient Education and Counseling, 2018, 101, 124-131.	2.2	31
45	T1-REDEEM: A Randomized Controlled Trial to Reduce Diabetes Distress Among Adults With Type 1 Diabetes. Diabetes Care, 2018, 41, 1862-1869.	8.6	63
46	When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation. Health and Quality of Life Outcomes, 2018, 16, 87.	2.4	10
47	Key Factors for Overcoming Psychological Insulin Resistanceâ€”An Examination of a Large International Sample through Content Analysis. Diabetes, 2018, 67, .	0.6	3
48	Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 371.	7.4	834
49	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. JAMA - Journal of the American Medical Association, 2017, 317, 379.	7.4	520
50	Diabetes distress is linked with worsening diabetes management over time in adults with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1228-1234.	2.3	99
51	Physicianâ€“patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDiaÂ® study. Diabetes Research and Clinical Practice, 2017, 127, 265-274.	2.8	35
52	Challenges faced by physicians when discussing the Type 2 diabetes diagnosis with patients: insights from a crossâ€national study (IntroDia^{Â®}). Diabetic Medicine, 2017, 34, 1100-1107.	2.3	13
53	The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial. Diabetes Care, 2017, 40, 736-741.	8.6	205
54	Investigating Hypoglycemic Confidence in Type 1 and Type 2 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 131-136.	4.4	68

#	Article	IF	Citations
55	Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100 U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials. Journal of Diabetes and Its Complications, 2017, 31, 562-568.	2.3	6
56	Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Annals of Internal Medicine, 2017, 167, 365.	3.9	385
57	Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 700-708.	11.4	99
58	Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully. International Journal of Clinical Practice, 2017, 71, e12973.	1.7	29
59	Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care, 2017, 40, 1425-1432.	8.6	213
60	Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 1469-1478.	8.6	112
61	Impact of an Automated Bihormonal Delivery System on Psychosocial Outcomes in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 723-729.	4.4	13
62	Assessing quality of life in diabetes: I. A practical guide to selecting the best instruments and using them wisely. Diabetes Research and Clinical Practice, 2017, 126, 278-285.	2.8	24
63	Exploring the role of the patientâ€“physician relationship on insulin adherence and clinical outcomes in type 2 diabetes: Insights from the MOSAIc study. Journal of Diabetes, 2017, 9, 596-605.	1.8	73
64	Assessing quality of life in diabetes: II â€“ Deconstructing measures into a simple framework. Diabetes Research and Clinical Practice, 2017, 126, 286-302.	2.8	28
65	Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Preference and Adherence, 2016, Volume 10, 1299-1307.	1.8	448
66	Impact of the Omnipod^{Â®} Insulin Management System on Quality of Life: A Survey of Current Users. Diabetes Technology and Therapeutics, 2016, 18, 664-670.	4.4	19
67	Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns. Diabetes Technology and Therapeutics, 2016, 18, 292-297.	4.4	37
68	Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). Journal of Diabetes Science and Technology, 2016, 10, 754-761.	2.2	18
69	The Impact of Real-Time Continuous Glucose Monitoring in Patients 65 Years and Older. Journal of Diabetes Science and Technology, 2016, 10, 892-897.	2.2	44
70	Prevalence of depression in Type 1 diabetes and the problem of overâ€diagnosis. Diabetic Medicine, 2016, 33, 1590-1597.	2.3	74
71	Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. Journal of Diabetes and Its Complications, 2016, 30, 1123-1128.	2.3	126
72	Type 2 Diabetes: Model of Factors Associated with Glycemic Control. Canadian Journal of Diabetes, 2016, 40, 424-430.	0.8	30

#	Article	IF	Citations
73	Understanding the Areas and Correlates of Diabetes-Related Distress in Parents of Teens With Type 1 Diabetes. Journal of Pediatric Psychology, 2016, 41, 750-758.	2.1	49
74	Poor medication adherence in diabetes: What's the problem?. Journal of Diabetes, 2015, 7, 777-778.	1.8	14
75	Perceived Accuracy in Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2015, 9, 339-341.	2.2	43
76	Development of a New Measure for Assessing Glucose Monitoring Device-Related Treatment Satisfaction and Quality of Life. Diabetes Technology and Therapeutics, 2015, 17, 657-663.	4.4	52
77	Understanding the sources of diabetes distress in adults with type 1 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 572-577.	2.3	253
78	When Does Personalized Feedback Make A Difference? A Narrative Review of Recent Findings and Their Implications for Promoting Better Diabetes Self-Care. Current Diabetes Reports, 2015, 15, 50.	4.2	34
79	Identifying the worries and concerns about hypoglycemia in adults with type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 1171-1176.	2.3	57
80	A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin?â€"Moving Toward Personalized Management of Type 2 Diabetes Mellitus. Postgraduate Medicine, 2014, 126, 135-144.	2.0	10
81	What is so tough about self-monitoring of blood glucose? Perceived obstacles among patients with TypeÂ2 diabetes. Diabetic Medicine, 2014, 31, 40-46.	2.3	38
82	Greater fear of hypoglycaemia with premixed insulin thanÂwith basalâ€bolus insulin glargine and glulisine: patientâ€reported outcomes from a 60â€week randomisedÂstudy. Diabetes, Obesity and Metabolism, 2014, 16, 1121-1127.	4.4	7
83	The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. Diabetic Medicine, 2014, 31, 764-772.	2.3	325
84	Toward Defining a Cutoff Score for Elevated Fear of Hypoglycemia on the Hypoglycemia Fear Survey Worry Subscale in Patients With Type 2 Diabetes. Diabetes Care, 2014, 37, 102-108.	8.6	46
85	What Are the Quality of Life-Related Benefits and Losses Associated with Real-Time Continuous Glucose Monitoring? A Survey of Current Users. Diabetes Technology and Therapeutics, 2013, 15, 295-301.	4.4	90
86	Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients. Diabetes Care, 2013, 36, 179-182.	8.6	66
87	When Is Diabetes Distress Clinically Meaningful?. Diabetes Care, 2012, 35, 259-264.	8.6	461
88	The impact of structured blood glucose testing on attitudes toward self-management among poorly controlled, insulin-naÃ¯ve patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 96, 149-155.	2.8	40
89	AASAP: A program to increase recruitment and retention in clinical trials. Patient Education and Counseling, 2012, 86, 372-377.	2.2	43
90	Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Current Medical Research and Opinion, 2011, 27, 1169-1174.	1.9	96

#	Article	IF	Citations
91	A survey of blood glucose monitoring in patients with type 2 diabetes: are recommendations from health care professionals being followed?. Current Medical Research and Opinion, 2011, 27, 31-37.	1.9	38
92	A Structured Self-Monitoring of Blood Glucose Approach in Type 2 Diabetes Encourages More Frequent, Intensive, and Effective Physician Interventions: Results from the STeP Study. Diabetes Technology and Therapeutics, 2011, 13, 797-802.	4.4	79
93	Patient perspectives on once-weekly medications for diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 144-149.	4.4	90
94	Structured Self-Monitoring of Blood Glucose Significantly Reduces A1C Levels in Poorly Controlled, Noninsulin-Treated Type 2 Diabetes. Diabetes Care, 2011, 34, 262-267.	8.6	384
95	Depression in Diabetes: Have We Been Missing Something Important?. Diabetes Care, 2011, 34, 236-239.	8.6	231
96	Perceived Treatment Efficacy: An Overlooked Opportunity in Diabetes Care. Clinical Diabetes, 2010, 28, 89-92.	2.2	20
97	The value of episodic, intensive blood glucose monitoring in non-insulin treated persons with type 2 diabetes: Design of the Structured Testing Program (STeP) Study, a cluster-randomised, clinical trial [NCT00674986]. BMC Family Practice, 2010, 11, 37.	2.9	25
98	Are Patientsâ€™ Initial Experiences at the Diagnosis of Type 2 Diabetes Associated With Attitudes and Self-management Over Time?. The Diabetes Educator, 2010, 36, 828-834.	2.5	22
99	Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. Current Medical Research and Opinion, 2010, 26, 1047-1054.	1.9	26
100	Patient perspectives on the role of weight management in type 2 diabetes. Diabetes Research and Clinical Practice, 2010, 88, 151-156.	2.8	4
101	Effective Use of Paired Testing in Type 2 Diabetes. The Diabetes Educator, 2009, 35, 915-927.	2.5	21
102	Diabetes Distress and Its Association with Clinical Outcomes in Patients with Type 2 Diabetes Treated with Pramlintide as an Adjunct to Insulin Therapy. Diabetes Technology and Therapeutics, 2008, 10, 461-466.	4.4	18
103	Psychological Insulin Resistance. The Diabetes Educator, 2007, 33, 241S-244S.	2.5	22
104	Assessing Psychosocial Distress in Diabetes: Development of the Diabetes Distress Scale. Diabetes Care, 2005, 28, 626-631.	8.6	1,087
105	A Community-Based Program to Encourage Patientsâ€™ Attention to Their Own Diabetes Care. The Diabetes Educator, 2005, 31, 691-699.	2.5	16
106	Psychological Insulin Resistance in Patients With Type 2 Diabetes: The scope of the problem. Diabetes Care, 2005, 28, 2543-2545.	8.6	490
107	Predictors of Diabetes-Specific Knowledge and Treatment Satisfaction Among Costa Ricans. The Diabetes Educator, 2004, 30, 281-292.	2.5	28
108	Integrating Medical Management With Diabetes Self-Management Training: A randomized control trial of the Diabetes Outpatient Intensive Treatment program. Diabetes Care, 2003, 26, 3048-3053.	8.6	126

#	Article	IF	Citations
109	Emotional and quality-of-life aspects of diabetes management. Current Diabetes Reports, 2002, 2, 153-159.	4.2	100
110	Assessment of Diabetes-Related Distress. Diabetes Care, 1995, 18, 754-760.	8.6	1,115
111	Correlates of hypoglycemic fear in Type I and Type II diabetes mellitus.. Health Psychology, 1992, 11, 199-202.	1.6	96
112	Immunological variability associated with experimentally-induced positive and negative affective states. Psychological Medicine, 1992, 22, 231-238.	4.5	42